Aprepitant: An oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy
- 1 January 2004
- journal article
- review article
- Published by Portico in Drugs of Today
- Vol. 40 (10) , 853-63
- https://doi.org/10.1358/dot.2004.40.10.863745
Abstract
This paper reviews the clinical profile of aprepitant, the first neurokinin-1 (NK(1)) receptor antagonist to be approved for use in the prevention of chemotherapy-induced nausea and vomiting. When given to patients receiving highly emetogenic chemotherapy, aprepitant in combination with a 5-hydroxytryptamine type-3 (5HT(3)) receptor antagonist and a corticosteroid provides significantly improved protection from chemotherapy-induced nausea and vomiting over that which has been previously achievable with current antiemetics.Keywords
This publication has 0 references indexed in Scilit: